SEXTON’S CT-5 IS A NEW APPROACH FOR PRODUCT FORMULATION AND FINAL FILL OF CELL AND GENE THERAPY PRODUCTS.
March 20, 2020
As with any manufacturing process, cell therapy manufacturing can be boiled down to a sequence of unit operations. The process starts with an input, runs through operations A, B, C, D, etc., and it ends with an output, generally using separate systems that do...
SEXTON BIOTECHNOLOGIES RAISES $5M TO ACCELERATE COMMERCIALIZATION OF COOK REGENTEC’S BIOPRODUCTION TOOLS
March 20, 2020
Sexton Biotechnologies announced today that it has raised $5 million in growth capital and is the first company incubated by Indianapolis-based Cook Regentec to secure outside investment capital and spin out as an independent biotechnology company. In...
GROWTH SUPPLEMENT BOOSTS CAR-T CELL PERFORMANCE – SEXTON BIOTECHNOLOGIES RELEASES T-CELL SPECIFIC HUMAN PLATELET LYSATE
March 20, 2020
Sexton Biotechnologies today announced the launch of T-Liven-PR, a T-Cell validated Human Platelet Lysate (hPL) shown to generate highly potent CAR-T Cells. T-Liven-PR, a pooled hPL treated with pathogen reduction technology, is released against a T-cell...